{"title":"Deucravacitinib治疗中度至重度斑块性银屑病","authors":"Steve Chaplin","doi":"10.1002/psb.2089","DOIUrl":null,"url":null,"abstract":"Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deucravacitinib for moderate to severe plaque psoriasis\",\"authors\":\"Steve Chaplin\",\"doi\":\"10.1002/psb.2089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.\",\"PeriodicalId\":20432,\"journal\":{\"name\":\"Prescriber\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Deucravacitinib for moderate to severe plaque psoriasis
Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
